top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Guy Levy Biography and Net Worth

Director of BioAtla

Guy Levy is the founder and Managing Member of Soleus Capital Management, L.P. ("Soleus"). His career spans 18 years in healthcare and life sciences. Prior to founding Soleus, Guy worked at Paulson & Co. where he was most recently a partner and portfolio manager. Prior to that, Guy worked as an investment analyst at Shumway Capital and Warburg Pincus. Guy began his career at Morgan Stanley, where he worked in the mergers & acquisitions and healthcare investment banking divisions. Guy holds a B.A. from Yale University, where he graduated summa cum laude.

How do I contact Guy Levy?: The corporate mailing address for Mr. Levy and other BioAtla executives is , , . BioAtla can also be reached via phone at 858-558-0708 and via email at [email protected]. Learn More on Guy Levy's contact information.
Has Guy Levy been buying or selling shares of BioAtla?: Guy Levy has not been actively trading shares of BioAtla during the last ninety days. Most recently, Guy Levy sold 546,709 shares of the business's stock in a transaction on Tuesday, August 24th. The shares were sold at an average price of $39.65, for a transaction totalling $21,677,011.85. Learn More on Guy Levy's trading history.
Who are BioAtla's active insiders?: BioAtla's insider roster includes Guy Levy (Director), Jay Short (CEO), Eric Sievers (Insider), Scott Smith (President), Lawrence Steinman (Director), Christian Vasquez (Insider), and Richard Waldron (CFO). Learn More on BioAtla's active insiders.
Are insiders buying or selling shares of BioAtla?: During the last year, BioAtla insiders bought shares 4 times. They purchased a total of 76,000 shares worth more than $162,400.00. The most recent insider tranaction occured on December, 26th when Director Sylvia Mcbrinn bought 4,000 shares worth more than $9,320.00. Insiders at BioAtla own 8.4% of the company. Learn More about insider trades at BioAtla.
Information on this page was last updated on 12/26/2023.

Guy Levy Insider Trading History at BioAtla

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/24/2021	Sell	546,709	$39.65	$21,677,011.85
12/18/2020	Buy	1,388,890	$18.00	$25,000,020.00

Guy Levy Buying and Selling Activity at BioAtla

BioAtla Company Overview

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $2.35

$2.24

$2.38

50 Day Range

MA: $2.79

$2.11

$3.92

2 Week Range

Now: $2.35

$1.24

$4.07

Volume

394,836 shs

Average Volume

510,042 shs

Market Capitalization

$113.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08